Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
NCT02976493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2019-08-20
Summary
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.
Conditions
Interventions
- OTHER
-
No Intervention
No Intervention
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-01
- Primary Completion
- 2018-06-18
- Completion
- 2018-06-18
Countries
- Japan
More Related Trials
-
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
NCT03126617 ·Status: NO_LONGER_AVAILABLE
-
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
NCT01309412 ·Status: TERMINATED ·Phase: PHASE1
-
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
NCT00752518 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01632150 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
NCT06163040 ·Status: COMPLETED
-
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
NCT02290431 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843 ·Status: RECRUITING ·Phase: PHASE1
-
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
NCT01849848 ·Status: COMPLETED ·Phase: PHASE2
-
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
NCT01568294 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
NCT02252263 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
NCT06232096 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
NCT02922543 ·Status: COMPLETED
-
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
NCT03393273 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
NCT05217082 ·Status: COMPLETED
-
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
NCT01556438 ·Status: COMPLETED ·Phase: PHASE1
-
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT03411031 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02497378 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
NCT01371227 ·Status: COMPLETED ·Phase: PHASE1
-
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT06956170 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
NCT06479954 ·Status: ACTIVE_NOT_RECRUITING
-
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
NCT04798586 ·Status: COMPLETED ·Phase: PHASE1